Long term side effects in schizophrenia outpatients under neuroleptic treatment

By Chinchilla A.   Vega M.   Cebollada A.   Padiacute n J.J.   Diacute az M.   Guzmaacute n G.   Montes J.M.  

European Neuropsychopharmacology, Vol. 5, Iss. 3, 1995-09 ,pp. : 344-344

Elsevier

Access to resources Recommend Favorite

Neuroleptic effectiveness prognosing in paranoid schizophrenia (clinical and neurophysiological aspects)

By Yurieva L.N.   Nosov S.G.  

European Neuropsychopharmacology, Vol. 5, Iss. 3, 1995-09 ,pp. : 324-324

Elsevier

Access to resources Recommend Favorite

Naltrexone augmentation of neuroleptic treatment in alcohol abusing patients with schizophrenia

By Petrakis Ismene   O’Malley Stephanie   Rounsaville Bruce   Poling James   McHugh-Strong Colette   Krystal John  

Psychopharmacology, Vol. 172, Iss. 3, 2004-03 ,pp. : 291-297

Springer Publishing Company

Access to resources Recommend Favorite

Naltrexone augmentation of neuroleptic treatment in alcohol abusing patients with schizophrenia

By Petrakis Ismene   O’Malley Stephanie   Rounsaville Bruce   Poling James   McHugh-Strong Colette   Krystal John  

Psychopharmacology, Vol. 174, Iss. 2, 2004-07 ,pp. : 300-300

Springer Publishing Company

Access to resources Recommend Favorite

Cognitive dysfunction in schizophrenia: comparison of treatment with a novel atypical antipsychotic agent versus conventional neuroleptic drugs

By Gallhofer B.  

European Neuropsychopharmacology, Vol. 5, Iss. 3, 1995-09 ,pp. : 200-201

Elsevier

Access to resources Recommend Favorite